<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01908933</url>
  </required_header>
  <id_info>
    <org_study_id>03-C13-001PLV</org_study_id>
    <nct_id>NCT01908933</nct_id>
  </id_info>
  <brief_title>Study of the AeriSeal System Treatment in Patients With Advanced Non-Upper Lobe Predominant Heterogeneous Emphysema</brief_title>
  <official_title>Study of the AeriSeal System Treatment in Patients With Advanced Non-Upper Lobe Predominant Heterogeneous Emphysema</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Aeris Therapeutics</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Aeris Therapeutics</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to prospectively evaluate the safety and efficacy of the
      AeriSeal System in patients with advanced Non-Upper Lobe Predominant Heterogeneous Emphysema.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a prospective single arm study to evaluate the safety and efficacy of the AeriSeal
      System in patients with advanced Non-Upper Lobe Predominant Heterogeneous Emphysema.
    </textblock>
  </detailed_description>
  <overall_status>Withdrawn</overall_status>
  <start_date>September 2013</start_date>
  <completion_date type="Actual">November 2013</completion_date>
  <primary_completion_date type="Anticipated">November 2013</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Volume change by CT</measure>
    <time_frame>28 - 30 weeks</time_frame>
    <description>Group mean normalized change from baseline in the volume of the treated lung lobes measured by quantitative CT at 24 weeks post-treatment (defined as the sum of volume change in all treated lobes/number of treatments).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Fraction of patients showing clinically significant improvements from baseline in one or more of the following outcomes at 24 weeks post treatment: Forced Expiratory Volume in 1 second (FEV1), Forced Vital Capacity (FVC), Medical Research Council Dyspnea</measure>
    <time_frame>28 - 30 weeks</time_frame>
    <description>Group mean change in baseline to week 24 in:Forced Expiratory Volume in 1 second (FEV1),Forced Vital Capacity (FVC),Medical Research Council Dyspnea (MRCD), 6 Six-Minute Walk Test (6MWT), Saint George Respiratory Questionnaire (SGRQ)</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">0</enrollment>
  <condition>Emphysema</condition>
  <condition>Chronic Obstructive Pulmonary Disease (COPD)</condition>
  <arm_group>
    <arm_group_label>AeriSeal Emphysematous Lung Sealant Syst</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>This is a prospective, open label, single-arm, multicenter, investigational study. Patients will receive either unilateral or bilateral AeriSeal System therapy as appropriate utilizing 20 mL/subsegment dosing at 2 to 4 subsegments.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>AeriSeal Emphysematous Lung Sealant Syst</intervention_name>
    <description>This is a prospective, open label, single-arm, multicenter, investigational study. Patients will receive either unilateral or bilateral AeriSeal System therapy as appropriate utilizing 20 mL/subsegment dosing at 2 to 4 subsegments.</description>
    <arm_group_label>AeriSeal Emphysematous Lung Sealant Syst</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Willing and able to provide informed consent and to participate in the study

          -  Age &gt; or = 40 years at the time of the screening

          -  Advanced lower or lower and upper lobe predominant heterogeneous emphysema by CT scan

          -  Minimum of 2 subsegments appropriate for treatment

          -  MRCD questionnaire score of 2 or greater at screening

          -  Failure of medical therapy to provide relief of symptoms

          -  Spirometry 15 minutes after administration of bronchodilator (BOTH):

               -  FEV1 &lt; 50 % predicted.

               -  FEV1/FVC ratio &lt;70 %

          -  Lung volumes by plethysmography (BOTH):

               -  Total Lung Capacity (TLC) &gt; 100 % predicted

               -  Residual Volume (RV) &gt; 150 % predicted

          -  Diffusing Capacity of Carbon Monoxide(DLco) &gt; = 20 and &lt; = 60 percent predicted

          -  Oxygen saturation (SpO2) &gt; 90 % on &lt; or = 4 L/min supplemental O2, at rest

          -  Six-Minute Walk Test distance &gt; or = 150 m

          -  Abstinence from smoking for at least 16 weeks prior to screening

        Exclusion Criteria:

          -  Prior lung volume reduction surgery, prior lobectomy or pneumonectomy, or prior lung
             transplantation

          -  Requirement for ventilator support (invasive or non-invasive)

          -  Three (3) or more COPD exacerbations requiring hospitalization within 1 year of
             Screening visit or a COPD exacerbation requiring hospitalization within 8 weeks of
             Screening visit

          -  Pulmonary hypertension, defined as:

               -  Echocardiogram with estimated peak systolic pressure &gt; 45 mmHg in the presence of
                  tricuspid valve regurgitation stated in the echocardiogram report

               -  If the echocardiogram shows peak systolic pressure &gt; 45 mmHg, right heart
                  catheterization is required to rule out pulmonary hypertension, defined as peak
                  systolic pressure &gt; 45 mmHg or mean pressure &gt; 35 mmHg

          -  Clinically significant asthma (reversible airway obstruction) or bronchiectasis

          -  CT scan: Presence of the following radiologic abnormalities:

               -  Pulmonary nodule on CT scan greater that 1.0 cm in diameter (Does not apply if
                  present for 2 years or more without increase in size or if proven benign by
                  biopsy/PET)

               -  Radiologic picture consistent with active pulmonary infection, e.g., unexplained
                  parenchymal infiltrate

               -  Significant interstitial lung disease

               -  Significant pleural disease

               -  Giant bullous disease (a predominant bulla &gt; 10 cm in all dimensions &gt;1 / 3 of
                  the hemithorax)

          -  Use of systemic steroids &gt; 20 mg/day or equivalent, immunosuppressive agents,
             heparins, oral anticoagulants (e.g., warfarin, dicumarol; note: antiplatelet drugs
             including aspirin and clopidogrel are permitted)

          -  Allergy or sensitivity to medications required to safely undergo AeriSeal System
             treatment

          -  Participation in an investigational study of a drug, biologic, or device not currently
             approved for marketing within 30 days prior to the screening visit

          -  Body mass index &lt; 15 kg/m2 or &gt; 35 kg/m2

          -  Female patient pregnant or breast-feeding or planning to be pregnant in the next year

          -  Significant comorbidity that carries prohibitive risks or is associated with less than
             2-year expected survival, including any of the following:

               -  HIV/AIDS

               -  Active malignancy

               -  Stroke or Transient Ischemia Attack (TIA) within 12 months of screening

               -  Myocardial infarction within 12 months of screening

               -  Congestive heart failure within 12 months of screening defined at clinical
                  evidence of right or left hear failure or left ventricular ejection fraction &lt; 45
                  % on echocardiogram

          -  Any condition that the Investigator believes would interfere with the intent of the
             study or would make participation not in the best interest of the patient such as
             alcoholism, high risk for drug abuse or noncompliance in returning for follow-up
             visits
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Felix Herth, Prof. Dr med</last_name>
    <role>Principal Investigator</role>
    <affiliation>Thoraxklinik am Uniklinikum Heidelberg</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Wolfgang Gesierich, Dr med</last_name>
    <role>Principal Investigator</role>
    <affiliation>Asklepios Fachkliniken Muenchen - Gauting</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Manfred Wagner, Dr med</last_name>
    <role>Principal Investigator</role>
    <affiliation>Klinikum Nuernberg Nord</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Mordechai Kramer, Prof</last_name>
    <role>Principal Investigator</role>
    <affiliation>Rabin Medical Center</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Martin Hetzel, Dr med</last_name>
    <role>Principal Investigator</role>
    <affiliation>Krankenhaus vom Roten Kreuz - Stuttgart</affiliation>
  </overall_official>
  <verification_date>November 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 18, 2013</study_first_submitted>
  <study_first_submitted_qc>July 24, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 26, 2013</study_first_posted>
  <last_update_submitted>November 13, 2013</last_update_submitted>
  <last_update_submitted_qc>November 13, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 14, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Advanced Emphysema</keyword>
  <keyword>Heterogeneous Lower Lobe Predominant Emphysema</keyword>
  <keyword>Heterogeneous Upper and Lower Lobe Predominant</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Diseases</mesh_term>
    <mesh_term>Lung Diseases, Obstructive</mesh_term>
    <mesh_term>Pulmonary Disease, Chronic Obstructive</mesh_term>
    <mesh_term>Emphysema</mesh_term>
    <mesh_term>Pulmonary Emphysema</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

